Comparing the current results to its competitors, Aytu Biopharma Inc reported Revenue decrease in the 3 quarter 2026 year on year by -34.86 %, despite the revenue increase by the most of its competitors of 1.81 %, recorded in the same quarter.
Aytu Biopharma Inc's Comment on Competition and Industry Peers
The Board regularly reviews the company's performance, prospects, and risks associated with the competitive landscape, including the entry of generic competitors, payor pressures, and new branded entrants. They evaluate potential partnerships, collaborations, acquisitions, or divestitures aimed at enhancing stockholder value. Management and the Board plan to continue assessing strategic transactions and business combinations, with a focus on growth in the prescription business, particularly regarding the opportunity for EXXUA in the MDD market.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.
Tenax Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing products for critical care patients with cardiovascular and pulmonary diseases. Their business model revolves around conducting research and clinical trials to bring innovative therapies to market. They generate revenue primarily by licensing their products to other pharmaceutical companies or through direct sales to hospitals and healthcare providers.
Petros Pharmaceuticals Inc is a pharmaceutical company that operates on a business model focused on the research, development, and commercialization of innovative drugs and therapeutics. They strive to bring new solutions to market by leveraging their expertise in various therapeutic areas, ultimately aiming to improve patient outcomes and well-being.
Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in the development and aseptic manufacturing of sterile injectable pharmaceuticals.
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Sources:
Aytu Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aytu Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
